News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Sharyn N. Lewin, MD, Holy Name Medical Center

Articles by Sharyn N. Lewin, MD, Holy Name Medical Center

Systemic Management of Ovarian Cancer: Closing Thoughts

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Novel Combination Strategies in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Recurrent Ovarian Cancer: Novel Agents Under Investigation

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Bevacizumab’s Role in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Recurrent Ovarian Cancer: Choosing a PARP Inhibitor

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

PARP Inhibition’s Role in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Frontline Ovarian Cancer Management: Ongoing Clinical Trials

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Considerations for the JAVELIN OVARIAN 100 Study

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Ovarian Cancer: Maintenance Following Frontline Bevacizumab

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Ovarian Cancer: Updates to NCCN Guidelines

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Treating Ovarian Cancer Based on HRD Status

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Ovarian Cancer: What is the Role of HRD Testing?

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Ovarian Cancer: Factors in Deciding on Maintenance Therapy

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Practical Applications of PRIMA in Ovarian Cancer Management

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

GOG-0218: Frontline Bevacizumab in Ovarian Cancer

ByBradley J. Monk, MD, Creighton University School of Medicine,Thomas J. Herzog, MD,Thomas C. Krivak, MD,Sharyn N. Lewin, MD, Holy Name Medical Center,Kathleen N. Moore, MD, MS, University of Oklahoma

May 27th 2020

Latest Updated Articles

Treating Ovarian Cancer Based on HRD Status
Published: May 27th 2020 | Updated:
SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer
Published: May 27th 2020 | Updated:
Ovarian Cancer: Updates to NCCN Guidelines
Published: May 27th 2020 | Updated:
Frontline Ovarian Cancer Management: Ongoing Clinical Trials
Published: May 27th 2020 | Updated:
Considerations for the JAVELIN OVARIAN 100 Study
Published: May 27th 2020 | Updated:
GOG-0218: Frontline Bevacizumab in Ovarian Cancer
Published: May 27th 2020 | Updated:

Trending on OncLive

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma

Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma